Smoothened Inhibitor, PF-04449913 Inhibits the Development of Myelofibrosis in a JAK2V617F Transgenic Mouse Model by...

Area of Science:

• Oncology
• Hematology
• Molecular Biology

Background:

• Myeloproliferative neoplasms (MPNs) driven by JAK2V617F mutations present challenges for current treatments like Ruxolitinib.
• Limited disease-modifying benefits of existing therapies necessitate exploration of novel therapeutic targets and pathways.

Purpose of the Study:

• To investigate the therapeutic potential of Smoothened inhibition (SMOi) using PF-04449913 in a JAK2V617F mouse model of MPNs.
• To elucidate the mechanistic effects of SMOi on key signaling pathways and disease phenotypes in JAK2V617F-driven MPNs.

Main Methods:

• Utilized a JAK2V617F transgenic mouse model and a murine bone marrow transplant model.
• Administered the small-molecule Smoothened inhibitor PF-04449913 (PF-13) to assess its effects on MPN phenotypes.
• Analyzed the impact of SMOi on splenomegaly, bone marrow fibrosis, allelic burden, and signaling pathways including Hh, pERK, NF-κB, and TGF-β.

Main Results:

• Hedgehog (Hh) signaling pathway is activated in JAK2V617F cells.
• SMOi significantly reduced splenomegaly and bone marrow fibrosis in JAK2V617F mice.
• SMOi decreased JAK2V617F allelic burden, reduced pERK and NF-κB signaling, and inhibited TGF-β signaling.

Conclusions:

• Smoothened inhibition is a viable therapeutic strategy for JAK2V617F-driven MPNs.
• SMOi exerts disease-modifying effects by targeting multiple key signaling pathways involved in MPN pathogenesis.
• This study provides critical mechanistic insights into the action of SMO inhibitors in MPNs, suggesting potential for novel therapeutic development.